Trinity Life Sciences Breaks Down the Barriers for Biopharmaceutical Companies to Gain Actionable Real World Evidence

Home / Media Center / News / Trinity Life Sciences Breaks Down the Barriers for Biopharmaceutical Companies to Gain Actionable Real World Evidence

Waltham, MA, September 21, 2020 – Trinity Life Sciences, a leader in global life sciences solutions, introduces Trinity EvidenceFirst™, a high-value subscription service that allows biopharmaceutical companies to take advantage of real-world insights like never before. EvidenceFirst allows organizations to benefit from big, robust data without dealing with the complexities, resource requirements, and costs associated with large data sets. With EvidenceFirst, biopharmaceutical companies can now utilize real-world insights on a broader range of projects with faster turnaround times. 

The combination of access to claims data, rigorous methodology, and expert interpretation of results makes EvidenceFirst the first of its kind. Timely insights allow biopharma companies to improve patient outcomes and drive commercial success. Within a week, EvidenceFirst can help HEOR and commercial teams answer four critical questions for a specific indication:

  • Who are the patients?
  • Where do I find them?
  • How are they treated?
  • What are their outcomes?

The answers to these questions are presented with consistent reporting that provides actionable insights. Not just a data pull, EvidenceFirst includes the “so what” provided by Trinity’s experts in a dependable format ready to be shared with internal business partners.

“Trinity EvidenceFirst allows pharmaceutical companies, for the first time, to get an early, foundational read on a market quickly, empowering them to identify risks and opportunities sooner,” said Dave Fitzhenry, CEO, Trinity. “The ability to bring timely, high-value, real-world insights to any point in the drug lifecycle is paramount to product and company success.”

EvidenceFirst is Fast, Convenient and Consistent

EvidenceFirst allows pharma companies to gain timely insights from data sources that they might not already have access to or struggle to gain in data sources they already own. The outputs and reporting are provided within a week and always consistent. Providing a predictable consistent set of foundational outputs is critical in building confidence among key internal stakeholders. This also arms biopharma leaders with a way to consistently compare across different populations.

For more information:                  
Elizabeth Marshall                  
Trinity Life Sciences                  

About Trinity Life Sciences

Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email